Literature DB >> 27547145

Transcatheter Closure of Iatrogenic VSDs after Aortic Valve Replacement Surgery: 2 Case Reports and a Literature Review.

John D S Taleyratne, Robert A Henderson.   

Abstract

We report 2 new cases of transcatheter closure of iatrogenic ventricular septal defects after aortic valve replacement surgery, together with our finding, in a literature review, of 9 additional patients who had undergone this procedure from 2004 through 2013. In all 11 cases, transcatheter device closure was indicated for a substantial intracardiac shunt with symptomatic heart failure, and such a device was successfully deployed across the iatrogenic ventricular septal defect, with clinical improvement. Our review suggests that transcatheter closure of iatrogenic ventricular septal defects in patients with previous aortic valve replacement surgery is a safe and effective treatment option, providing anatomic defect closure and relief of symptoms in the short-to-medium term.

Entities:  

Keywords:  Aortic valve insufficiency/replacement/surgery; catheterization; echocardiography, transesophageal; heart septal defects, ventricular/therapy; iatrogenic disease; septal occluder device; ventricular septum/injuries

Mesh:

Year:  2016        PMID: 27547145      PMCID: PMC4979393          DOI: 10.14503/THIJ-15-5083

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


  8 in total

1.  Transcatheter closure of iatrogenic perimembranous ventricular septal defect following prosthetic aortic valve replacement.

Authors:  F Dodos; W Fehske; U Hoppe; N Sreeram
Journal:  Clin Res Cardiol       Date:  2007-11-20       Impact factor: 5.460

2.  Transcatheter closure of iatrogenic perimembranous ventricular septal defect after aortic valve and ascending aorta replacement using an Amplatzer membranous ventricular septal occluder.

Authors:  Maciej Chojnicki; Adam Sukiennik; Lech Anisimowicz; Iwona Swiatkiewicz; Wojciech Pawliszak
Journal:  Cardiol J       Date:  2008       Impact factor: 2.737

3.  Percutaneous device closure of congenital and iatrogenic ventricular septal defects in adult patients.

Authors:  Wail Al-Kashkari; Prakash Balan; Clifford J Kavinsky; Qi-Ling Cao; Ziyad M Hijazi
Journal:  Catheter Cardiovasc Interv       Date:  2010-10-06       Impact factor: 2.692

4.  Percutaneous closure of iatrogenic ventricular septal defect following surgical aortic valve replacement using two different approaches.

Authors:  Takashi Matsumoto; Wen-Loong Yeow; Saibal Kar
Journal:  J Invasive Cardiol       Date:  2013-02       Impact factor: 2.022

5.  How should I treat a perimembranous interventricular defect following aortic valve replacement surgery?

Authors:  Michele Coceani; Marco Ciardetti; Mathis Schlueter; Cataldo Palmieri; Gennaro Santoro; Sergio Berti
Journal:  EuroIntervention       Date:  2012-12-20       Impact factor: 6.534

6.  Transcatheter membranous ventricular septal defect closure through a mechanical aortic prosthesis using the Amplatzer membranous ventricular septal defect occluder.

Authors:  Stéphane Noble; Réda Ibrahim
Journal:  Catheter Cardiovasc Interv       Date:  2009-02-01       Impact factor: 2.692

7.  Device closure of iatrogenic membranous ventricular septal defects after prosthetic aortic valve replacement using the Amplatzer membranous ventricular septal defect occluder.

Authors:  Ralf Holzer; Larry Latson; Ziyad M Hijazi
Journal:  Catheter Cardiovasc Interv       Date:  2004-06       Impact factor: 2.692

8.  Percutaneous closure of an iatrogenic ventricular septal defect following mechanical aortic valve replacement using the transseptal technique.

Authors:  Andrew J Klein; Joel A Garcia; John D Carroll
Journal:  Catheter Cardiovasc Interv       Date:  2007-12-01       Impact factor: 2.692

  8 in total
  1 in total

1.  Transcatheter Closure of Residual and Iatrogenic Ventricular Septal Defects: Tertiary Center Experience and Outcome.

Authors:  Fatma A Taha; Fareed Alnozha; Osama Amoudi; Mansour Almutairi; Reda Abuelatta
Journal:  Pediatr Cardiol       Date:  2021-09-08       Impact factor: 1.655

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.